

## Devyser strengthens its management team

Devyser is today announcing the strengthening and expanding of its management team as of February 1, 2024. Michael Uhlin, who has been Devyser's CSO since the fall of 2023, will join the management team, with responsibility for development /innovation, including bioinformatics, clinical affairs and Devyser Genomic Laboratories, Devyser's CLIA-certified laboratory. He will report to Devyser's CEO, Fredrik Alpsten.

Michael Uhlin, who also holds a professorship at Karolinska Institutet, has solid experience in the global life sciences sector, in both academia and industry, where he has held various senior positions. He has long been engaged in translational research and development in areas relevant to Devyser's activities.

*"Devyser is on a steep growth trajectory and we need to both reinforce and optimize the way we work. I am very pleased to see Michael join the management team as part of this process. With his solid experience and clinical background, he has a very important role in the company when it comes to driving our ongoing growth",* says Fredrik Alpsten, Devyser's CEO.

Following Michael Uhlin's appointment, the company's management team will comprise Fredrik Alpsten, CEO, Sabina Berlin, CFO, Theis Kipling, CCO, Göran Rydin, COO, Michael Uhlin, CSO, and Camilla Wiberg, CHRO.

**For more information, please contact:**

Fredrik Alpsten, CEO

E-mail: [fredrik.alpsten@devyser.com](mailto:fredrik.alpsten@devyser.com)

Telephone: +46 70 667 31 06



**PRESS RELEASE**

29 January 2024 14:15:00 CET

### **About Devyser**

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit [www.devyser.com](http://www.devyser.com).